Joseph E. Maakaron, Tatyana A. Feldman, Todd A. Fehniger, Gunjan L. Shah, Amitkumar Mehta, Dipenkumar Modi, Matthew Genyeh Mei, Craig Sauter, Rashmi Khanal, Stefan K. Barta, Joseph Maly, Michael Emig, Lydia Wunderle, Andre Overesch, Kerstin Pietzko, Alexandra Vasile, Jennifer Rubel, Thorsten Graef, Heather Raymon, Alison J. Moskowitz. "Results from the completed dose-finding part of phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203).." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.7008